Related Experiment Videos

[An experimental study of ototoxicity induced by deferoxamine mesilate]

S Yamanobe1, H Kanno

  • 1Fukushima Medical University.

Insights

Deferoxamine mesilate (DFO) may cause ototoxicity. High doses of DFO in guinea pigs led to elevated compound action potential thresholds and outer hair cell damage, indicating potential hearing loss risks.

Area of Science:

  • Ototoxicology
  • Pharmacology
  • Neuroscience

Context:

  • Deferoxamine mesilate (DFO) is a chelating agent used in treating iron overload.
  • Potential side effects of DFO, including ototoxicity, require thorough investigation.
  • Understanding drug-induced hearing loss is crucial for patient safety.

Purpose:

  • To investigate the ototoxic potential of deferoxamine mesilate (DFO) in a guinea pig model.
  • To assess the effects of DFO administration on auditory function and cochlear integrity.
  • To determine the dose-dependent relationship between DFO exposure and hearing impairment.

Summary:

  • Guinea pigs received varying doses of DFO (200, 400, or 600 mg/kg/day) or saline for several weeks.
  • Auditory function was evaluated by measuring compound action potential (CAP) and endocochlear potential (EP) thresholds.
  • Cochlear histology was examined using scanning electron microscopy to assess hair cell damage.

Impact:

  • DFO administration at 600 mg/kg/day resulted in significantly elevated CAP thresholds and decreased EP values.
  • Histological analysis revealed missing outer hair cells in the cochlea of animals treated with the highest DFO dose.
  • DFO-induced hair cell damage is a contributing factor to elevated CAP thresholds, suggesting a risk of hearing loss with high-dose DFO treatment.

Related Concept Videos